肠易激综合征与幽门螺杆菌感染相关性的研究
发布时间：2018-08-06 19:41
【摘要】：目的:探究肠易激综合征(irritable bowel syndrome,IBS)与幽门螺杆菌(helicobacter pylori,HP)感染情况之间的关联性。方法:选取IBS患者共120例,健康体检者共120例,通过14C尿素呼气和快速尿素酶法检测,分析肠易激综合征与幽门螺杆菌感染情况之间的相关性;再者,按照IBS亚型,将HP阳性的IBS患者分为研究组与对照组,两组同时给予匹维溴铵50mg,(便秘型IBS口服伊托必利50mg)每日3次,连续治疗4周,同时研究组在此基础上加用三联疗法(奥美拉唑20mg,克拉霉素0.5g加阿莫西林1g)治疗HP感染,每日2次,持续2周,分别计算各亚型在研究组与对照组中的治疗总有效率。结果:(1)幽门螺杆菌(HP)的感染率及其差异:120例肠易激综合征(IBS)患者中有73人感染HP,感染率为60.8%;健康查体组的120例中有54人感染HP,感染率为45%,两组之间有显著性统计学差异(P0.01);(2)肠易激综合征(IBS)各亚型间HP感染率及其比较:试验组120例患者中便秘型19例,HP感染率为47.3%(9/19);腹泻型16例,HP感染率为75%(12/16);混合型16例,HP感染率为75%(12/16);未分化型69例,HP感染率为58%(40/69),肠易激综合征(IBS)各亚型之间HP感染率的比较有统计学差异(P0.05);(3)HP阳性的肠易激综合征(IBS)各亚型治疗的总有效率为:腹泻型治疗总有效率(100%)显著高于对照组(20%),两者之间有显著性统计学差异(P0.01);便秘型治疗的总有效率(100%)高于相应的对照组(0%),存在统计学差异(P0.05);混合型治疗的总有效率(100%)高于对照组(16.7%),两者的比较有统计学意义(P0.05);未定型治疗的总有效率(75%)高于对照组(30%),有统计学意义(P0.05)。结论:(1)HP感染与肠易激综合征存在相关性;(2)HP感染在肠易激综合征各亚型之间有统计学的差异,两者密切相关;(3)幽门螺杆菌的治疗是IBS各亚型的治疗总有效率的决定因素之一。
[Abstract]:Objective: to investigate the relationship between (irritable bowel syndrome and helicobacter pylori infection. Methods: 120 patients with IBS and 120 healthy controls were selected to analyze the correlation between irritable bowel syndrome and Helicobacter pylori infection by 14C urea breath and rapid urease assay. Furthermore, according to the IBS subtype, Patients with HP positive IBS were divided into two groups: the study group and the control group. The patients in the two groups were given 50mg of piveronium bromide at the same time. The patients with constipated IBS were treated with itopride 50mg three times a day for 4 weeks. At the same time, the study group was treated with triple therapy (omeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g) for HP infection twice a day for 2 weeks. The total effective rates of each subtype in the study group and the control group were calculated. Results: (1) the infection rate of Helicobacter pylori (HP) and its difference were found in 73 out of 120 patients with irritable bowel syndrome (IBS) and 54 patients in the healthy check-up group (P < 0.05). There were significant statistics between the two groups. The infection rate of HP among the (IBS) subtypes of irritable bowel syndrome (P0.01); (2) and its comparison: the infection rate of constipation type was 47.3% (9 / 19), diarrhea type was 75% (12 / 16), mixed type was 75% (12 / 16), undifferentiated type 69%. The infection rate of HP was 58% (40 / 69) in patients with irritable bowel syndrome (IBS). There was significant difference in HP infection rate among the subtypes of irritable bowel syndrome (P0.05); (3). The total effective rate of HP positive (IBS) subtypes was: the total effective rate of diarrhea type treatment (100%) was significantly higher than that of the control group (100%). The total effective rate of constipation treatment (100%) was higher than that of the corresponding control group (0%) (P0.05), the total effective rate of mixed therapy (100%) was higher than that of the control group (16.7%), the total effective rate of constipation treatment (100%) was higher than that of the control group (16.7%). The total effective rate of unstereotyped treatment (75%) was significantly higher than that of the control group (30%) (P0.05). Conclusion: (1) HP infection is associated with irritable bowel syndrome (IBS), (2) HP infection is significantly different among the subtypes of IBS, and (3) the treatment of Helicobacter pylori is one of the determinants of the total effective rate of each subtype of IBS.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R574.4
，
本文编号：2168788
[Abstract]:Objective: to investigate the relationship between (irritable bowel syndrome and helicobacter pylori infection. Methods: 120 patients with IBS and 120 healthy controls were selected to analyze the correlation between irritable bowel syndrome and Helicobacter pylori infection by 14C urea breath and rapid urease assay. Furthermore, according to the IBS subtype, Patients with HP positive IBS were divided into two groups: the study group and the control group. The patients in the two groups were given 50mg of piveronium bromide at the same time. The patients with constipated IBS were treated with itopride 50mg three times a day for 4 weeks. At the same time, the study group was treated with triple therapy (omeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g) for HP infection twice a day for 2 weeks. The total effective rates of each subtype in the study group and the control group were calculated. Results: (1) the infection rate of Helicobacter pylori (HP) and its difference were found in 73 out of 120 patients with irritable bowel syndrome (IBS) and 54 patients in the healthy check-up group (P < 0.05). There were significant statistics between the two groups. The infection rate of HP among the (IBS) subtypes of irritable bowel syndrome (P0.01); (2) and its comparison: the infection rate of constipation type was 47.3% (9 / 19), diarrhea type was 75% (12 / 16), mixed type was 75% (12 / 16), undifferentiated type 69%. The infection rate of HP was 58% (40 / 69) in patients with irritable bowel syndrome (IBS). There was significant difference in HP infection rate among the subtypes of irritable bowel syndrome (P0.05); (3). The total effective rate of HP positive (IBS) subtypes was: the total effective rate of diarrhea type treatment (100%) was significantly higher than that of the control group (100%). The total effective rate of constipation treatment (100%) was higher than that of the corresponding control group (0%) (P0.05), the total effective rate of mixed therapy (100%) was higher than that of the control group (16.7%), the total effective rate of constipation treatment (100%) was higher than that of the control group (16.7%). The total effective rate of unstereotyped treatment (75%) was significantly higher than that of the control group (30%) (P0.05). Conclusion: (1) HP infection is associated with irritable bowel syndrome (IBS), (2) HP infection is significantly different among the subtypes of IBS, and (3) the treatment of Helicobacter pylori is one of the determinants of the total effective rate of each subtype of IBS.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R574.4
，
本文编号：2168788
本文链接：https://www.wllwen.com/yixuelunwen/xiaohjib/2168788.html
最近更新
教材专著
